✦ LIBER ✦

PCN42 Treatment Costs of Bone Metastases in Patients with Lung Cancer: Results From A French Prospective, Observational, Multicenter Study (GFPC 0601)

✍ Scribed by Borget, I.; Decroisette, C.; David, P.; Fournel, P.; Locher, C.; Grangeon, V.; Thomas, P.; Barlesi, F.; Bombaron, P.; Chouaid, C.

Book ID: 122190770
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 62 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.1143

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ESTIMATED COSTS OF HER2-POSITIVE METASTA

ESTIMATED COSTS OF HER2-POSITIVE METASTATIC BREAST CANCER FOR PATIENTS INITIATING AN ORAL ANTICANCER TREATMENT: RESULTS FROM A FRENCH PROSPECTIVE OBSERVATIONAL STUDY

✍ Woronoff-Lemsi, M.C.; Chaix-Couturier, C.; Durand-Zaleski, I.; Espié, M.; Lortho 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

9148 POSTER Incidence of Bone Metastases

9148 POSTER Incidence of Bone Metastases and Skeletal-related Events in Patients With Advanced Lung Cancer – Results of a Multicenter, Prospective, Cohort Study (CSP-HOR13)

✍ Seki, N.; Eguchi, K.; Katakami, N.; Kunikane, H.; Takeda, K.; Takayama, K.; Sawa 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Health-resource utilization attributable

Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: results of the US cohort from a multicenter observational study

✍ Aftab Mahmood; Hassan Ghazal; Marsha G. Fink; Mehool Patel; Carolyn Atchison; Ra 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 841 KB

6549 POSTER Treatment of recurrent or pr

6549 POSTER Treatment of recurrent or progressive brain metastases with patupilone in patients with non-small cell lung cancer (NSCLC): results of a multicenter, open-label phase II study

✍ Abrey, L.; Johri, A.; Wen, P.Y.; Govindan, R.; Reimers, H.J.; Robins, H.I.; de B 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB